Charles Schwab’s AIM ImmunoTech AIM Stock Holding History

Charles Schwab’s Portfolio AIM Stock Details AIM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-203	Closed	-$44K	–	3610
2021 Q2	$44K	Hold	203	–	–	﹤0.01%	3389
2021 Q1	$47K	Hold	203	–	–	﹤0.01%	3443
2020 Q4	$37K	Hold	203	–	–	﹤0.01%	3363
2020 Q3	$44K	Hold	203	–	–	﹤0.01%	3287
2020 Q2	$51K	Buy	+203	New	+$49.3K	﹤0.01%	3260

Other funds holding AIM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab's AIM Position: Q3 2021 in Review

Charles Schwab sold out of AIM ImmunoTech (AIM) in Q3 2021, closing a stake of 203 shares — an estimated $44K sold.

Charles Schwab first reported a position in AIM in Q2 2020 and held it in 5 quarters. The position peaked at $51K in Q2 2020. 36 funds tracked by Wall St. Rank hold AIM as of Q3 2021.

Charles Schwab reported no remaining AIM ImmunoTech position as of Q3 2021 after selling out during the quarter.
Charles Schwab sold 203 AIM ImmunoTech shares in Q3 2021, an estimated $44K.
Charles Schwab first reported a position in AIM ImmunoTech in Q2 2020 and held it in 5 quarters.
Charles Schwab's AIM ImmunoTech position peaked at $51K in Q2 2020.
36 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q3 2021.

Based on Charles Schwab's 13F filing for Q3 2021, filed 16 Nov 2021.